Aripiprazole (Long-Acting Injection) (Abilify Maintena (monthly) and Abilify Asimtufii (every 2 months) — Otsuka Pharmaceutical / Lundbeck Canada)

Atypical (second-generation) antipsychotic

Aripiprazole (Long-Acting Injection) (Abilify Maintena (monthly) and Abilify Asimtufii (every 2 months) — Otsuka Pharmaceutical / Lundbeck Canada)

Forms and strengths
Form: InjectionStrength: Maintena: 300 mg or 400 mg vial/syringe, monthly; Asimtufii: 720 mg/2.4 mL or 960 mg/3.2 mL syringe, every 2 months
Print

Indication

  • Treatment of schizophrenia in adult patients — both Maintena (monthly) and Asimtufii (every two months) are indicated, with efficacy established in acute and maintenance phases.
  • Maintenance monotherapy treatment of bipolar I disorder in adult patients — both products share this indication.
  • Asimtufii's efficacy and safety are based on the clinical trials that established Abilify Maintena's efficacy and safety, plus pharmacokinetic bridging data: in a randomized, parallel-arm study, Asimtufii 960 mg given once every two months was shown to provide similar aripiprazole concentrations to Maintena 400 mg given monthly over the dosing interval — Asimtufii itself was not separately proven in fresh efficacy trials.

Rejoining the server...

Rejoin failed... trying again in seconds.

Failed to rejoin.
Please retry or reload the page.

The session has been paused by the server.

Failed to resume the session.
Please retry or reload the page.